PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
Information source: Medtronic Cardiac Rhythm Disease Management
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Left Ventricular Dysfunction
Intervention: RV lead placement site (Other)
Phase: N/A
Status: Recruiting
Sponsored by: Medtronic Cardiac Rhythm Disease Management Official(s) and/or principal investigator(s): Dr. Gerald Kaye, Study Chair, Affiliation: Princess Alexandra Hospital
Overall contact: Natalie Middleton Middleton, Email: natalie.middleton@medtronic.com
Summary
This study will be done in patients who require the implantation of a cardiac pacemaker (an
electronic device that controls the heartbeat) for complete heart block (a heart rhythm
abnormality resulting in a slow heart beat). Pacemakers regulate the heart beat by
delivering pulses of electricity through special wires (pacing leads) which are placed
inside the heart.
This study will compare two groups of pacemaker patients. Each group will have their pacing
leads placed in a particular location in the heart. The purpose of the study is to show
whether the position used in one group is better for maintaining effective heart function
compared to the position used in the other group.
The leads in one group will be placed in a position called the Right Ventricular Apex. This
is the traditional and most frequently used position for pacemaker leads.
The leads in the other group will be placed in a position called the Right Ventricular High
Septum. This is a less commonly used position, but may result in health benefits for the
patients compared with the Right Ventricular Apex.
Clinical Details
Official title: PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing. Does Right Ventricular High-Septal Pacing Improve Outcome Compared With Right Ventricular Apical Pacing?
Study design: Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Efficacy Study
Primary outcome: Comparison of change in Left Ventricular Ejection Fraction between the two patient groups.
Secondary outcome: Incidence of atrial tachyarrhythmia recorded by the pacemakersWorsening of heart failure All cause mortality Incidence of stroke N-Terminal Brain Natriuretic Peptide (NT-proBNP) levels Echocardiographic measures of left ventricular dyssynchrony 6 minute Hall-Walk distance
Detailed description:
There is an increasing amount of evidence to suggest that other positions in the heart may
be more effective than the conventional Right Ventricular Apex (RVA) position for restoring
good heart function. The best site to place a lead has not yet been proven.
This is a study comparing the long term clinical effects of two different lead positions.
The measurements taken to assess the clinical effects include:
- the effectiveness of the heart's pumping action (as measured by ultrasound scans)
- measurements of how far patients can walk in 6 minutes
- analysis of blood samples
- collection of information from the pacemaker about heart rhythm problems
Half of the patients in the study will receive conventional leads placed in the more common
RVA position in the heart. The other half will receive a relatively new type of lead placed
in what is called the Right Ventricular High Septal (RVHS) position.
In order to fairly compare the outcomes of these two different lead positions this study has
been designed as a 'randomized', 'blind' trial. This means that the group which patients
will be entered into will be chosen at random and patients will not be told which group they
are in.
Patients will each have an equal (50: 50) chance of being in either group. By carefully
comparing the clinical differences between the two groups of patients, the study aims to
prove whether or not there are additional benefits for patients when the RVHS lead position
is used.
All leads used in the study have been shown to be safe for patients and are available
commercially for implantation. All of the implanting doctors involved in the study are
experienced at implanting the pacemakers and leads that will be used in this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients with high grade AV block and sinus rhythm, scheduled to undergo dual chamber
pacemaker implantation OR patients with high grade AV block and permanent atrial
fibrillation, scheduled to undergo single chamber ventricular pacemaker implantation.
- Patients aged 18 years or older.
Exclusion Criteria:
- Patients indicated for an Implantable Cardioverter Defibrillator or Cardiac
Resynchronization Therapy.
- Patients following junctional ablation.
- Patients with a Myocardial Infarction within three months prior to enrollment.
- Patients that received bypass surgery within three months prior to enrollment.
- Patients that had a valve replacement within three months prior to enrollment or
patients with a mechanical right heart valve.
- Patients where a right ventricular lead cannot be placed i. e. complex congenital
heart disease.
- Patients with hypertrophic obstructive cardiomyopathy.
- Patients with acute coronary syndrome, unstable angina, severe mitral regurgitation
and/or hemodynamically significant aortic stenosis.
- Previous implanted pacemaker or cardioverter defibrillator.
- Known paroxysmal atrial fibrillation or a documented episode of atrial fibrillation
prior to enrollment.
- Patients on amiodarone therapy within the last six months prior to enrollment.
- Terminal conditions with a life expectancy of less than two years.
- Participation in any other study that would confound the results of this study.
- Psychological or emotional problems that may interfere with the volunteer's ability
to provide full consent or fully understand the purposes of the study.
- Pregnant patients or patients who may become pregnant during the time-scale of the
study.
Locations and Contacts
Natalie Middleton Middleton, Email: natalie.middleton@medtronic.com
Auckland City Hospital, Auckland, New Zealand; Recruiting Kelly Reynish, Phone: +64 9 630 9923 Nigel Lever, Principal Investigator
Christchurch Hospital, Christchurch, New Zealand; Recruiting Bronwyn Davies, Phone: +64 3 3641096 Ian Crozier, Principal Investigator
James Cook University Hospital, Middlesbrough, United Kingdom; Recruiting Dr. Nick Linker, Principal Investigator
Royal Bournemouth Hospital, Bournemouth, United Kingdom; Recruiting Dr. Adrian Rozkovec, Principal Investigator
Leeds General Infirmary, Leeds, United Kingdom; Recruiting Dr. Chris Pepper, Principal Investigator
Princess Royal Hospital, Orpington, Kent, United Kingdom; Recruiting Dr. Steve Sutcliffe, Principal Investigator
St. Thomas' Hospital, London, United Kingdom; Recruiting Dr. Aldo Rinaldi, Principal Investigator
University Hospital of Wales, Cardiff, United Kingdom; Recruiting Dr. Zaheer Yousef, Principal Investigator
New Cross Hospital, Wolverhampton, United Kingdom; Recruiting Dr. Rajpal Singh, Principal Investigator
Blackpool Victoria Hospital, Blackpool, United Kingdom; Recruiting Dr. Graham Goode, Principal Investigator
Colchester General, Colchester, United Kingdom; Recruiting Dr. Kare Tang, Principal Investigator
Norfolk and Norwich University Hospital, Norwich, United Kingdom; Recruiting Dr. Ian Williams, Principal Investigator
The Prince Charles Hospital, Brisbane, Queensland, Australia; Recruiting Steve Graves, Phone: 07 3139 4711 Russell Denman, Principal Investigator
Royal Brisbane & Womens' Hospital, Brisbane, Queensland, Australia; Recruiting Leeanne Palethorpe, Phone: 07 3636 5281 Paul Martin, Principal Investigator
Princess Alexandra Hospital, Brisbane, Queensland, Australia; Recruiting Cindy Hall, Phone: 07 3240 7676 Gerald Kaye, Principal Investigator
Royal Adelaide Hospital, Adelaide, South Australia, Australia; Recruiting Vanessa Maxwell, Phone: 08 8222 5789 Glenn Young, Principal Investigator
Calvary Wakefield Hospital, Adelaide, South Australia, Australia; Recruiting AnneMarie Mitchell, Phone: 08 82234288 Glenn Young, Principal Investigator
Flinders Medical Center, Adelaide, South Australia, Australia; Recruiting Bel Vuljanic, Phone: 08 8404 2007 Andrew McGavigan, Principal Investigator
Additional Information
Starting date: May 2007
Ending date: April 2012
Last updated: April 23, 2009
|